Piper Jaffray Expands Healthcare Equity Research with the Hiring of Tyler Van Buren
January 23 2018 - 5:23PM
Business Wire
Piper Jaffray Companies (NYSE: PJC), a leading investment bank
and asset management firm, is pleased to announce the hiring of
Tyler Van Buren as a senior research analyst responsible for
covering biotechnology companies. He will be based in the firm’s
New York office.
In 2017, Institutional Investor recognized Van Buren as the No.
1 Rising Star in the specialty pharma category and the No. 2 Rising
Star across therapeutics. He joins Piper Jaffray from Cowen and
Company, where he was an equity research analyst covering large and
smid-cap biopharma companies for five years. Prior to that, Van
Buren was a founding member and managing director at New York-based
LifeSci Advisors, where he helped build the firm’s biotechnology
research practice. Earlier in his career, he worked at Amylin
Pharmaceuticals, Lithera Pharmaceuticals, the Sanford-Burnham
Medical Research Institute and the U.S. Department of
Agriculture.
“Tyler brings a breadth of both industry and sell-side
experience across biopharma, biotech and the broader healthcare
space. This addition will add strength to our firm’s overall
leadership in the healthcare sector and add immediate value for our
clients,” said Michael Cox, director of equity research at Piper
Jaffray.
Van Buren earned a master’s degree in biology and a bachelor’s
degree in biochemistry and cellular biology from the University of
California, San Diego.
The Piper Jaffray equity research group consists of 40 senior
analysts covering 680 companies across the following sectors:
consumer, energy, financial services, healthcare, industrials &
business services, and technology.
About Piper JaffrayPiper Jaffray Companies (NYSE: PJC) is
a leading investment bank and asset management firm. Securities
brokerage and investment banking services are offered in the U.S.
through Piper Jaffray & Co., member SIPC and FINRA; in Europe
through Piper Jaffray Ltd. and Simmons & Company International
Limited, authorized and regulated by the U.K. Financial Conduct
Authority; and in Hong Kong through Piper Jaffray Hong Kong
Limited, authorized and regulated by the Securities and Futures
Commission. Asset management products and services are offered
through five separate investment advisory affiliates―U.S.
Securities and Exchange Commission (SEC) registered Advisory
Research, Inc.; Piper Jaffray Investment Management LLC, PJC
Capital Partners LLC and Piper Jaffray & Co.; and
Guernsey-based Parallel General Partners Limited, authorized and
regulated by the Guernsey Financial Services Commission.
Follow Piper Jaffray: LinkedIn | Facebook | Twitter
© 2018 Piper Jaffray Companies, 800 Nicollet Mall, Suite 1000,
Minneapolis, Minnesota 55402-7036
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180123006575/en/
Piper Jaffray CompaniesPamela Steensland,
612-303-8185analystmediarelations@pjc.com
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Jul 2023 to Jul 2024